Prarthna Bhardwaj

@TumorBoardTues @YAbdouMD @IntegrityCE @drteplinsky @IlanaSchlam @PTarantinoMD @royaryam @JasmineSukumar @maryam_lustberg @gandhi_shipra @hmcarthur @ncasasanta @nerealiamd @dradityabardia @SirohiBhawna @jhaveri_komal @elmayermd @KalinskyKevin #PostTest Q2️⃣ #TumorBoardTuesday 👉🏽 Free CME 🔗 integrityce.com/TBT26 🧐 In the phase 3 lidERA trial of adjuvant giredestrant (G) vs SOC ET what was shown❓

@TumorBoardTues @YAbdouMD @IntegrityCE @drteplinsky @IlanaSchlam @PTarantinoMD @royaryam @JasmineSukumar @maryam_lustberg @gandhi_shipra @hmcarthur @ncasasanta @nerealiamd @dradityabardia @SirohiBhawna @jhaveri_komal @elmayermd @KalinskyKevin #PostTest Q1️⃣ #TumorBoardTuesday 👉🏽#CME Eval 🔗 integrityce.com/TBTeval26 👉🏽ALL CME🔗 integrityce.com/TBT26 🤔What 2L Tx would you offer a 54yo♀️w/ ESR1m HR+/HER2- mBC w/ PD on 1L CDK4/6i + AI?

#TumorBoardTuesday Good morning @TumorBoardTues crowd - looking forward to diving back into the learning, as we exit winter🌨️ 📢Join us Tuesday, 3-3-26 at 8PM ET as @YAbdouMD & @prarthnavb 🗣️the use of oral SERDs in HR+ metastatic #breastcancer RT and bring others into the discussion‼️

@MPishvaian @TumorBoardTues @YAbdouMD @IntegrityCE @drteplinsky @IlanaSchlam @PTarantinoMD @royaryam @JasmineSukumar @maryam_lustberg @gandhi_shipra @hmcarthur @ncasasanta @nerealiamd @dradityabardia @SirohiBhawna @jhaveri_komal @elmayermd @KalinskyKevin Yes pre-emptive change of treatment with development of an ESR1m w/o radiologic progression. Clinical trial suggested doing it at routine mBC f/u intervals which is usually q3m

@prarthnavb @TumorBoardTues @YAbdouMD @IntegrityCE @drteplinsky @IlanaSchlam @PTarantinoMD @royaryam @JasmineSukumar @maryam_lustberg @gandhi_shipra @hmcarthur @ncasasanta @nerealiamd @dradityabardia @SirohiBhawna @jhaveri_komal @elmayermd @KalinskyKevin #TumorBoardTuesday So this is a change of therapy pre-emptively❓ 🤔How often would they look for development of the ESR1m❓

@TumorBoardTues @YAbdouMD @IntegrityCE @drteplinsky @IlanaSchlam @PTarantinoMD @royaryam @JasmineSukumar @maryam_lustberg @gandhi_shipra @hmcarthur @ncasasanta @nerealiamd @dradityabardia @SirohiBhawna @jhaveri_komal Any idea why the combination was not approved by the FDA in all comers or even with ESR1m?

@TumorBoardTues @YAbdouMD @IntegrityCE @drteplinsky @IlanaSchlam @PTarantinoMD @royaryam @JasmineSukumar @maryam_lustberg @gandhi_shipra @hmcarthur @ncasasanta @nerealiamd @dradityabardia @SirohiBhawna 10/22 #TumorBoardTuesday Board Bite: Perform Liquid NGS testing at progression! Currently approved oral SERDs in HR+HER2- mBC 📋Elacestrant → EMERALD study @dradityabardia 📋Imlunestrant → EMBER-3 study @jhaveri_komal

@MPishvaian @TumorBoardTues @YAbdouMD @IntegrityCE @drteplinsky @IlanaSchlam @PTarantinoMD @royaryam @JasmineSukumar @maryam_lustberg @gandhi_shipra @hmcarthur @ncasasanta @nerealiamd @dradityabardia @SirohiBhawna Great point! When you look at 5 year IDFS difference between tamoxifen and AI, that was marginal at 2-4%. However, there is some expectation to see improvement over time. Particularly imp for HR+ disease with late recurrences.

@prarthnavb @TumorBoardTues @YAbdouMD @IntegrityCE @drteplinsky @IlanaSchlam @PTarantinoMD @royaryam @JasmineSukumar @maryam_lustberg @gandhi_shipra @hmcarthur @ncasasanta @nerealiamd @dradityabardia @SirohiBhawna #TumorBoardTuesday My initial reaction to the iDFS/OS data above was - is 1-2% worth it❓ BUT....if Giredestrant is slightly more effective but actually slightly better tolerated, then that does seem worth it - no❓